18 patents
Utility
Somatostatin modulators and uses thereof
5 Dec 23
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Sangdon Han, Sun Hee Kim, Yunfei Zhu
Filed: 6 Apr 22
Utility
Crystalline forms of a somatostatin modulator
3 Oct 23
Described herein are crystalline forms of 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide, uses of such crystalline forms in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a somatostatin modulator compound.
Yuxin Zhao, Jayachandra P. Reddy, Lauren Maceachern, Samer Kahwaji, Evans Monyoncho, Peter Mueller
Filed: 16 Feb 22
Utility
Somatostatin modulators and uses thereof
21 Mar 23
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jian Zhao, Shimiao Wang, Yunfei Zhu
Filed: 11 Feb 19
Utility
Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
31 Jan 23
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
Sangdon Han, Yunfei Zhu, Sun Hee Kim, Jian Zhao, Shimiao Wang
Filed: 8 Feb 21
Utility
Nonpeptide somatostatin type 5 receptor agonists and uses thereof
25 Oct 22
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jian Zhao, Yunfei Zhu, Shimiao Wang, Mi Chen, Joseph Pontillo
Filed: 10 Aug 20
Utility
Somatostatin modulators and uses thereof
16 Aug 22
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jian Zhao, Sangdon Han, Sun Hee Kim, Shimiao Wang, Yunfei Zhu
Filed: 26 Oct 20
Utility
Formulations of a somatostatin modulator
8 Mar 22
Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Gerald Burke, Ian Yates, Hannah Bulovsky, Kyle Kyburz, Clayton Tyler
Filed: 7 Sep 21
Utility
Somatostatin modulators and uses thereof
30 Nov 21
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Sangdon Han, Sun Hee Kim, Yunfei Zhu
Filed: 19 May 20
Utility
Somatostatin modulators and uses thereof
27 Jul 21
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Sangdon Han, Sun Hee Kim, Yunfei Zhu
Filed: 16 Sep 19
Utility
Somatostatin modulators and uses thereof
8 Jun 21
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jian Zhao, Yunfei Zhu, Shimiao Wang, Sangdon Han, Sun Hee Kim
Filed: 24 Jul 18
Utility
Process of making somatostatin modulators
12 Jan 21
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jayachandra P. Reddy, Mahmoud Mirmehrabi
Filed: 3 Oct 19
Utility
Somatostatin modulators and uses thereof
28 Dec 20
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jian Zhao, Shimiao Wang, Yunfei Zhu
Filed: 11 Dec 19
Utility
Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
7 Sep 20
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
Sangdon Han, Yunfei Zhu, Sun Hee Kim, Jian Zhao
Filed: 12 Dec 19
Utility
Somatostatin modulators and uses thereof
29 Jun 20
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Sangdon Han, Sun Hee Kim, Yunfei Zhu
Filed: 16 Sep 19
Utility
Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
30 Mar 20
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
Sangdon Han, Yunfei Zhu, Sun Hee Kim, Jian Zhao, Shimiao Wang
Filed: 26 Aug 19
Utility
Somatostatin modulators and uses thereof
23 Mar 20
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jian Zhao, Shimiao Wang, Yunfei Zhu
Filed: 7 May 19
Utility
Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
17 Feb 20
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
Sangdon Han, Yunfei Zhu, Sun Hee Kim, Jian Zhao, Shimiao Wang
Filed: 4 Jun 19
Utility
Process of making somatostatin modulators
4 Nov 19
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jayachandra P. Reddy, Mahmoud Mirmehrabi, Madhukar Kota, Uttam Dash
Filed: 15 Jan 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first